Pfizer promotes Canada chief to lead US primary care marketing

Share this article:
Pfizer named Paul Levesque chief marketing officer for its US primary care business.

Levesque was previously primary care general manager and country lead for Canada, and before that served VP marketing for Pfizer Canada and France. As CMO, he's responsible for marketing Pfizer's primary care drugs in the US and reports to Adele Gulfo, president and general manager, US Primary Care.

“Primary care physicians are the core of the US healthcare system and Pfizer's US primary care organization is a significant part of our biopharmaceutical business,” said Gulfo in a statement. “Paul Levesque's 26 years of sales and marketing experience in the pharmaceutical industry, including 20 years with Pfizer, makes him ideally suited to lead our primary care marketing efforts in the US.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...